Skip to main content
Clinical Trials/NCT05669430
NCT05669430
Recruiting
Phase 1

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

GV20 Therapeutics13 sites in 1 country268 target enrollmentMarch 23, 2023

Overview

Phase
Phase 1
Intervention
GV20-0251
Conditions
Not specified
Sponsor
GV20 Therapeutics
Enrollment
268
Locations
13
Primary Endpoint
Objective Response Rate ORR per RECIST version 1.1 (Parts B and D)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Detailed Description

This is a Phase 1/2A non-randomized, open label, multi-center study to be conducted in four parts (Parts A, B, C and D). In Part A, a 3+3 dose escalation scheme will be used to evaluate the safety and tolerability of GV20-0251, and to establish the maximum tolerated dose (MTD) or the preliminary recommended Phase 2 dose (RP2D). In Part B, the Bayesian optimal design for Phase II (BOP2) will be utilized to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 at the preliminary RP2D across multiple expansion cohorts involving eligible participants. In Part C, the Bayesian optimal interval (BOIN) design will be employed to evaluate the safety and tolerability of GV20-0251 in combination with Pembrolizumab, and to determine the MTD or the preliminary RP2D of this combination. In Part D, BOP2 will be applied to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 in combination with Pembrolizumab at the preliminary RP2D across multiple expansion cohorts involving eligible participants.

Registry
clinicaltrials.gov
Start Date
March 23, 2023
End Date
September 5, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants ≥18 years of age
  • Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy
  • Refractory or intolerant to standard therapy(ies)
  • Must have received, be not eligible or decline standard of care therapy
  • Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
  • For participants who have received prior treatment with a checkpoint inhibitor there must be documented disease progression
  • ECOG performance status of 0 or 1
  • Life expectancy of ≥ 12 weeks in Parts A and C and ≥ 24 weeks in Parts B and D
  • Participants must be willing to provide fresh tumor biopsy (core biopsy) both pre-treatment (Parts A, B, C and D) and on-treatment (Parts A and B), if clinically feasible
  • Disease-free of active second/secondary or prior malignancies for ≥ 2 years

Exclusion Criteria

  • Participant with acute leukemia or CLL (Parts A and B only)
  • Participant with heart disease or unstable arrhythmia
  • Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
  • Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy
  • History of major organ transplant
  • History of a bone marrow transplant
  • Symptomatic central nervous system (CNS) malignancy or metastasis
  • Serious nonmalignant disease
  • Pregnant or nursing women
  • Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication

Arms & Interventions

Part A - Dose Escalation in up to 7 dose levels

A 3+3 dose escalation scheme will be used to evaluate the safety and tolerability of GV20-0251, and to establish the maximum tolerated dose (MTD) or the preliminary recommended Phase 2 dose (RP2D).

Intervention: GV20-0251

Part B - Multiple Expansion Cohorts in up to 4 tumor indications

The Bayesian optimal design for Phase II (BOP2) will be utilized to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 at the preliminary RP2D in up to 4 expansion cohorts involving eligible participants.

Intervention: GV20-0251

Part C - GV20-0251 in Combination with Pembrolizumab Dose Escalation in 2-4 dose levels

The Bayesian optimal interval (BOIN) design will be employed to evaluate the safety and tolerability of GV20-0251 in combination with pembrolizumab, and to determine the MTD or the preliminary RP2D of this combination in selected tumor indications.

Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]

Part D - GV20-0251 in Combination with Pembrolizumab Dose Expansion in up to 5 indications

The BOP2 will be applied to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 in combination with pembrolizumab at the preliminary RP2D in up to 5 expansion cohorts involving eligible participants.

Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]

Outcomes

Primary Outcomes

Objective Response Rate ORR per RECIST version 1.1 (Parts B and D)

Time Frame: 12 months

ORR

Percentage of Participants With Adverse Events (Parts A and C)

Time Frame: 12 months

Secondary Outcomes

  • nADAs(12 months)
  • Overall Survival (Parts B and D)(24 months)
  • Additional safety and tolerability(24 months)
  • Cmax of GV20-0251(12 months)
  • Tmax of GV20-0251(12 months)
  • T1/2(12 months)
  • AUC(12 months)
  • ADAs(12 months)
  • DCR(24 months)
  • DoR(24 months)
  • PFS(24 months)
  • ORR (Parts A and C)(24 months)

Study Sites (13)

Loading locations...

Similar Trials

Related News

GV20 Therapeutics to Present AI-Designed Immune Checkpoint Inhibitor Data for Advanced Melanoma at ASCO 2025- GV20 Therapeutics will present updated Phase 1 data on GV20-0251, the first AI-designed antibody targeting the novel immune checkpoint IGSF8, at ASCO 2025. - The presentation will showcase clinical and translational findings from patients with advanced solid tumors resistant to anti-PD(L)1 therapies, with a focus on melanoma patients showing primary resistance. - GV20-0251 represents a significant advancement in AI-driven drug discovery, having progressed from target identification to IND filing in just three years with promising early efficacy data.GV20 Therapeutics Partners with Mitsubishi Tanabe to Develop Novel AI-Discovered Antibody-Drug Conjugates- GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens. - The partnership will utilize GV20's proprietary STEAD AI platform for antibody discovery combined with MTPC's expertise in linker-payload technology to advance innovative cancer therapeutics. - Under the agreement, GV20 will receive an upfront payment plus milestone payments, while MTPC gains exclusive negotiation rights for licensing the antibodies during the collaboration period.GV20 Therapeutics Reports First Clinical Data for AI-Designed Checkpoint Inhibitor GV20-0251 in Advanced Solid Tumors- GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8. - The study enrolled 38 heavily pre-treated patients and demonstrated favorable safety with no dose-limiting toxicities across all dose levels from 0.5 to 20 mg/kg. - Two confirmed partial responses were observed in 12 evaluable metastatic cutaneous melanoma patients, with 14 of 29 patients showing stable disease including tumor shrinkage. - The drug showed dose-proportional pharmacokinetics with a 25.6-day half-life and full target occupancy on circulating T cells at doses ≥3 mg/kg.